Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Herbal Galactogogues: a Double-blinded, Placebo-controlled Randomized Trial.
Brief Summary: The purpose of this study is to assess the effectiveness of a commercially available product containing a combination of Silybum marianum and Galega officinalis to support continuation or augmentation of breast milk production.


Options:
A: Inclusion Criteria:

* All pregnant women with pregestational or gestational diabetes under diet or insulin control

Exclusion Criteria:

* Patient who have epilepsy or on anti-seizure medications,
* Patients who have a history of significant depression or are on antidepressant drugs
* Patients who have pheochromocytoma or uncontrolled hypertension
* Patients who have intestinal bleeding or obstruction
* Patient with known allergy or prior reaction to metoclopramide
* Patient with HIV infection
* Current pregnancy complicated by fetal congenital anomalies and multiple fetuses
B: Inclusion Criteria:

* singleton, term delivery
* \>2.5 kg newborn weight
* lactation-deficiency

Exclusion Criteria:

* Neonatal Intensive Care Unit admission
* use of galactagogue drugs
* allergy
C: Inclusion Criteria:

* age 20 to 45 years at delivery
* received prenatal care in Kaiser Permanente Northern California (KPNC) health care system
* Gestational Diabetes (GDM) pregnancy diagnosed using the 3-hour 100 g OGTT by Carpenter and Coustan criteria
* delivered a singleton, live birth \>= 35 weeks gestation
* no pre-existing diabetes or other serious medical conditions prior to index GDM pregnancy
* no diabetes diagnosis (2-hour 75 gram OGTT) at 6 to 9 weeks postpartum for the index GDM pregnancy
* no use of thyroid medications, steroids, or other medications affecting glucose tolerance
* not planning to move from the northern California area within the subsequent 24 months
* not planning another pregnancy within the next two years
* Two infant feeding groups: women who did not lactate or did so for less than 3 weeks, OR women who provided no supplemental milk feeds at 2-4 weeks and planned to continue intensive lactation defined as \<= 1 formula supplement (6 oz/day) from 6-9 weeks until 4 months or more postpartum.

Exclusion criteria:

* Women who fed both breast milk and 7-16 oz of formula (mixed feeding) during the first 4 weeks of life
D: Inclusion Criteria:

* Mothers 2-12 weeks postpartum
* Mothers with term infants 37 weeks gestation or older
* Mothers with poor milk supply documented by professional lactation consultants
* Mothers whose milk supply is less than 600 cc per 24 hours
* Mothers who agree not to breastfeed or provide their milk to their infants during this study

Exclusion Criteria:

* Mothers with documented mastitis
* Mothers with breast engorgement
* Mothers with inverted nipples
* Maternal BMI greater than 35
* Mothers currently consuming Reglan, Domperidone or other drugs/herbals used to induce milk production
* Mothers who are clinically ill or hospitalized, or taking the following medications:

  1. Diuretics
  2. Pseudoephedrine
  3. Anticholinergics
  4. Warfarin or any anticoagulant
  5. An estrogen-containing birth control pill
* Mothers with Diabetes mellitus
* Mothers who have had breast surgery that could alter milk synthesis or production
* Mothers diagnosed with Polycystic ovary syndrome
* Mothers with tubular breasts or breasts with insufficient glandular tissue
* Mothers diagnosed with Asthma or atopic disease
* Mothers who are known to be allergic to peanuts or soybeans
* Mothers who are pregnant
* Mothers whose milk supply per 24 hours exceeds 600 mL
* Mothers with Obstetrical evaluation recommending exclusion

Answer: B